Everything on Clinical Research

Larger trial enrollments in China reduce statistical error rates (Type I/II), increasing trial success rates and decreasing abandoned development pipelines.

Impact: Higher statistical power improves decision-making accuracy, reduces wasted R&D spend, and accelerates the commercialization of viable therapies.

— from China's Biotech Surge: Regulatory Reform and Market Strategy · a16z Podcast· Apr 29, 2026